Nasser Mousa | Public Health | Best Researcher Award

Published on by Scientific World Research Awards

Prof. Dr. Nasser Mousa | Public Health | Best Paper Award

Professor | Mansoura University | Egypt

Prof. Dr. Nasser Hamed Mousa is a renowned Egyptian medical scientist and hepatologist, serving at the Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. With a Scopus record of 1,028 citations, 47 scientific publications, and an h-index of 16, he has made exceptional contributions to the fields of hepatology, gastroenterology, metabolic diseases, and translational medicine. Prof. Mousa earned his M.B.B.Ch., M.Sc., and Ph.D. in Hepatology and Gastroenterology from leading Egyptian medical universities, where he developed a strong foundation in internal medicine and liver pathology. Over the years, he has built an impressive professional career focusing on clinical hepatology, particularly viral hepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). His research interests encompass liver disease surveillance, nanomedicine, cancer biology, and metabolic dysfunction-associated steatotic liver disease (MASLD). Notably, his recent studies on individualized HCC risk stratification and gold nanoparticle-mediated cancer therapy have gained international recognition for their innovative clinical and molecular insights. Prof. Mousa’s research skills span molecular diagnostics, clinical trial design, bioinformatics-based network pharmacology, and predictive modeling for liver disease outcomes, reflecting his multidisciplinary expertise. His collaboration with national and international research teams underscores his leadership in evidence-based hepatology. Prof. Mousa has also contributed to advancing precision medicine approaches for patients with chronic liver disease, integrating laboratory science with clinical decision-making. Throughout his career, he has received numerous academic honors and institutional recognitions for his excellence in research, publication impact, and contribution to medical innovation. In conclusion, Prof. Dr. Nasser Hamed Mousa stands as a distinguished figure in liver research, embodying excellence in scientific inquiry, clinical innovation, and academic leadership, while his impactful body of work continues to influence global hepatology and improve patient outcomes in Egypt and worldwide.

Profiles: Scopus | ORCID 

Featured Publications

  1. Mousa, N., Elbaz, S., Elmetwalli, A., Mansour, M., Abdelsalam, M., Abdelaziz, M., Hashem, M., El-Emam, O., El-wakeel, N., Elgamal, A., et al. (2025). A risk stratification score for predicting first episode of upper gastrointestinal bleeding in patients with cirrhosis. Archives of Medical Research.

  2. Mousa, N., Elmetwalli, A., Abdel-Razik, A., Mousa, E., Abdelsalam, M., Elbaz, S., El-wakeel, N., Eldars, W., Gad, E., Arafa, M., et al. (2025, September 15). Periodontitis and metabolic dysfunction-associated steatotic liver disease: Emphasizing the clinical interplay between hepatologists and dentists. Odontology.

  3. Mousa, N., Elbaz, S., Elmetwalli, A., Abdelsalam, M., Abdelkader, E., Wahba, M., Abdelaziz, M., El-Emam, O., El-wakeel, N., Shaheen, M., et al. (2025, April 16). Neutrophil percentage-to-albumin ratio as a predictor of acute kidney injury in cirrhotic patients: A novel approach utilizing artificial intelligence. American Journal of Nephrology.

  4. Shiha, G., Mousa, N., Soliman, R., Mikhail, N. N. H., Elbasiony, M. A., & Khattab, M. (2020, July). Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. Journal of Viral Hepatitis.

  5. Elbaz, S., Mousa, N., Besheer, T., Sheta, T., Taha, K., Awad, M., Effat, N., Elgamal, A., & Abdel-Razik, A. (2020, April 2). Malondialdehyde and C-reactive protein as prognostic markers of hepatocellular carcinoma. British Journal of Biomedical Science.

 

Shinichiro Sawa | Medicine | Best Researcher Award

Published on by Scientific World Research Awards

Dr. Shinichiro Sawa | Medicine | Best Researcher Award

Professor | Kyushu University | Japan 

Dr. Shinichiro Sawa is a highly accomplished Japanese immunologist and medical researcher renowned for his pioneering work in immune regulation, autoimmunity, and inflammation. He currently serves as a Professor at the Institute of Bioregulation, Kyushu University, Japan, where he leads innovative studies in molecular and cellular immunology. Dr. Sawa began his academic journey at Osaka University, earning his Medical Degree (M.D.) in 2000 and subsequently his Ph.D. in Medicine in 2006 from the same institution, where he developed a strong foundation in biomedical sciences and experimental medicine. His professional trajectory includes significant academic roles as Assistant Professor at the University of Tokyo (2011–2016) and Associate Professor at Hokkaido University’s Institute for Genetic Medicine (2016–2018) before joining Kyushu University in 2019. Dr. Sawa’s research interests center on understanding how immune cells, such as γδ T cells, fibroblasts, and plasma cells, interact with tissue environments to regulate immune tolerance, autoimmunity, and inflammatory diseases. His studies, published in prestigious journals such as Nature Immunology, Journal of Clinical Investigation, and Journal of Investigative Dermatology, have shed light on how fibroblasts contribute to central immune tolerance and how plasma cells promote osteoclastogenesis in autoimmune arthritis. His research skills encompass cellular immunology, molecular signaling analysis, animal modeling of immune diseases, flow cytometry, and translational immunopathology, demonstrating both depth and precision in experimental design and interpretation. Recognized for his scientific contributions, Dr. Sawa has received numerous academic honors and research recognitions throughout his career, reflecting his influence in the global immunology community. In conclusion, Dr. Shinichiro Sawa stands as a leading figure in immunological research, bridging basic science and clinical application to advance our understanding of immune homeostasis and to pave the way for novel therapeutic strategies against autoimmune and inflammatory disorders.

Profiles: Scopus | ORCID

Featured Publications

  1. Nonaka, D., Yoshida, S., Nakano, K., Li, X., Okamura, T., Umemoto, E., Yamada, T., Watanabe, M., Jinno, S., Ito, M., Tsuda, M., Noguchi, N., Jiang, X.-J., Sumiya, E., & Sawa, S. (2025). Fibroblast-derived CSF1 maintains colonization of gut mucosal macrophage to resist bacterial infection. Mucosal Immunology.

  2. Onji, M., Sigl, V., Lendl, T., Novatchkova, M., Ullate-Agote, A., Andersson-Rolf, A., Kozieradzki, I., Koglgruber, R., Pai, T.-P., Lichtscheidl, D., Nayak, K., Zilbauer, M., Carranza García, N.-A., Sievers, L., Falk-Paulsen, M., Cronin, S. J. F., Hagelkruys, A., Sawa, S., Osborne, L. C., Rosenstiel, P., Pasparakis, M., Ruland, J., Takayanagi, H., Clevers, H., Koo, B.-H., & Penninger, J. M. (2025). RANK drives structured intestinal epithelial expansion during pregnancy. Nature, 637(8044), 156–166.

  3. Nitta, T., Tsutsumi, M., Nitta, S., Muro, R., Suzuki, E. C., Nakano, K., Tomofuji, Y., Sawa, S., Okamura, T., Penninger, J. M., & Takayanagi, H. (2020). Fibroblasts as a source of self-antigens for central immune tolerance. Nature Immunology, 21(10), 1172–1180.

  4. Nagashima, K., Sawa, S., Nitta, T., Tsutsumi, M., Okamura, T., Penninger, J. M., Nakashima, T., & Takayanagi, H. (2017). Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nature Immunology, 18(6), 675–682.

  5. Onder, L., Mörbe, U., Pikor, N., Novkovic, M., Cheng, H.-W., Hehlgans, T., Pfeffer, K., Becher, B., Waisman, A., Rülicke, T., Gommerman, J., Müller, C., Sawa, S., Scandella, E., & Ludewig, B. (2017). Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity, 47(1), 80–92.